MRUS News and Press, Merus N.V.

2024-07-01 08:11:31 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus announces pricing of upsized public offering of common shares Read the full article on Seeking Alpha For further details see: Merus names Fabia...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...

2024-06-27 10:45:04 ET Aurora Innovation Inc (AUR) AUR is trading UP for the last 5 days, and it at trading at $2.79 with volume of 1,962,658 and a one day change of $0.15 (5.67%). Aurora Innovation Inc has a 52-week low of 1.30 and a 52-week high of $4.81. The business's 50-day mov...

2024-06-17 09:00:05 ET Bradley Canino from Stifel Nicolaus issued a price target of $99.00 for MRUS on 2024-06-17 07:26:00. The adjusted price target was set to $99.00. At the time of the announcement, MRUS was trading at $56.55. The overall price target consensus is at ...

2024-06-04 09:00:06 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for MRUS on 2024-06-04 08:08:00. The adjusted price target was set to $88.00. At the time of the announcement, MRUS was trading at $52.94. The overall price target consensus...

2024-06-04 08:00:13 ET Etzer Darout from BMO Capital issued a price target of $91.00 for MRUS on 2024-06-04 06:48:00. The adjusted price target was set to $91.00. At the time of the announcement, MRUS was trading at $52.94. The overall price target consensus is at $71.60...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...

2024-05-30 03:10:38 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...